Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials.

ABSTRACT: Type 2 diabetes mellitus (T2DM) is highly prevalent in the general population and especially in patients with heart failure (HF). It is not only a risk factor for incident HF, but is also associated with worse outcomes in prevalent HF. Therefore, antihyperglycaemic management in patients at risk of or with established HF is of importance to reduce morbidity/mortality. Following revision of the drug approval process in 2008 by the Food and Drug Administration and European Medicines Agency, several cardiovascular outcome trials on antihyperglycaemic drugs have recently investigated HF endpoints. Signals of harm in terms of increased risk of HF have been identified for thiazolidinediones and the dipeptidyl peptidase 4 inhibitor saxagliptin, and therefore, these drugs are not currently recomme

SUBMITTER: Savarese G 

PROVIDER: S-EPMC7755024 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature